Navigation Links
Ironwood Appoints Thomas McCourt As Chief Commercial Officer and Senior Vice President of Marketing and Sales
Date:9/14/2009

CAMBRIDGE, Mass., Sept. 14 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. today announced that Thomas McCourt has joined the Company as chief commercial officer and senior vice president of marketing and sales. Mr. McCourt will be responsible for overall commercial strategy and execution and will lead Ironwood's growing marketing and sales team.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081006/NEM080ALOGO )

Mr. McCourt comes to Ironwood from Amgen, where he led the U.S. brand team for denosumab, a novel biologic under review at the FDA for the treatment of bone diseases and Amgen's first potential primary care product. Previously, he was with Novartis, where he directed the launch and growth of Zelnorm(R) for the treatment of patients with IBS-C and chronic constipation and held a number of senior commercial roles, including vice president of strategic marketing and operations. Mr. McCourt was also part of the founding team at Astra Merck, leading the development of the medical affairs and science liaison group and then serving as brand manager for Prilosec(R), the blockbuster therapy for the treatment of gastroesophageal reflux disease. Mr. McCourt has a degree in pharmacy from the University of Wisconsin.

"We are very pleased that Tom has joined our team," said Peter Hecht, CEO of Ironwood. "Tom's unique knowledge of gastrointestinal product marketing and his multiple experiences bringing breakthrough medicines to the market will be invaluable as we and our partners prepare to bring linaclotide to IBS-C and chronic constipation patients around the world."

"It's wonderful to be at Ironwood. I am impressed with the quality of the people and the high level of science," said Mr. McCourt. "I am extremely excited to have the opportunity to hel
'/>"/>

SOURCE Ironwood Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Microbia Announces Name Change to Ironwood Pharmaceuticals
2. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
3. Codexis Appoints Singapore Laboratories Managing Director
4. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
5. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
6. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
9. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
10. NeurogesX Appoints New Director to the Board
11. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 Sinovac Biotech Ltd. ... products in China , today announced that ... quarter ended June 30, 2014, after market close on Thursday, ... call prior to the market opening on Friday, August 15, ... 8:00 p.m. China Standard Time) to review the Company,s financial ...
(Date:7/24/2014)... 24, 2014 Gain recognition for ... Chain of the biotech industry. Nominations are now ... brought to you by the Bio Supply ... supply chain management professionals for the past 7 ... of the Biotech industry – Manufacturers, Service Providers, ...
(Date:7/24/2014)... Calif. , July 24, 2014  ECC West ... Denver, Colorado with University College Hospital (UCH) ... a development project to finance, design, construct, and operate ... Nigeria . Under the first of ... prepare scoping documents and funding applications. UCH Ibadan intends ...
(Date:7/24/2014)... to materialise. Yet, scientists are making progress in ... One such approach relies on quantum dotsa kind ... electric field. A new study demonstrates that changing ... (TQDs) with electrical impulses can help better control ... be used as quantum information units, which would ...
Breaking Biology Technology:Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... Covance Inc. (NYSE:,CVD) today announced that it will ... Tuesday, May 13, 2008 at 10:30 am ET. Investors ... http://www.covance.com . In order to,register and download any necessary ... headquarters in Princeton, New Jersey, is one of the,world,s ...
... SAN CLEMENTE, Calif., May 12 USGI Medical, ... that the company has,licensed its incisionless surgery technology ... robotics applications. Financial terms of the deal,were not ... and clinical development,including their intellectual property," said Gary ...
... Bulletin Board: NURX pre split, NUXP post split) today ... split became,effective. The Company has been informed by the ... connection with the reverse stock,split, its trading symbol has ... split will reduce the number of issued and,outstanding shares ...
Cached Biology Technology:USGI Medical Licenses Incisionless Surgery Technology to Intuitive Surgical 2USGI Medical Licenses Incisionless Surgery Technology to Intuitive Surgical 3NuRx Pharmaceuticals Announces Change of Ticker Symbol to NUXP, Reverse Stock Split Now in Effect 2
(Date:7/25/2014)... (NRG1) is a pleiotropic factor characterized by the ... of exons that confer to the protein deeply ... both the myelination occurring during development and the ... nerve: axon degeneration, axon regrowth, remyelination and target ... have discovered that the soluble NRG1 upregulation observed ...
(Date:7/25/2014)... The routine use of a molecular testing panel ... performing the correct initial surgery for patients with ... University of Pittsburgh Cancer Institute (UPCI), partner with ... Multidisciplinary Thyroid Center and other diagnostic testing agencies, ... initial surgery by 30 percent, according to the ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... diet with large amounts of vegetables and fish gives a ... to be published by the Sahlgrenska Academy at the University ... that a Mediterranean diet, based on a high consumption of ... such as meat and milk, leads to better health., ...
... WEST LAFAYETTE, Ind. - Bacteria are able to ... disease - by manipulating a natural cellular process. , ... revealed how a pair of proteins from the bacteria Legionella ... order to divert raw materials within the cell for use in ...
... project from LIFE the Faculty of Life Sciences at ... a different growth pattern than non-breastfed children. Breastfeeding lowers the ... blood, which means that growth is slightly slower. This is ... in life. The PhD project is part of ...
Cached Biology News:Purdue scientists reveal how bacteria build homes inside healthy cells 2Purdue scientists reveal how bacteria build homes inside healthy cells 3Breastfeeding promotes healthy growth 2
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
Reactivity: Human...
... Transformation Kit is designed for rapid ... Advantages over commonly used transformation procedures ... methods include:- Cells can be made competent ... cell preparation and transformation solutions are ...
...
Biology Products: